Recent News

 

Stay up to date on the latest news about Abpro, including press releases and upcoming publications.

 

News

Press Releases

March 25, 2025
Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025
Read More →
March 10, 2025
Abpro Statement on the Departure of Former CEO Ian Chan
Read More →
DEC 12, 2024
Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing
Read More →
JAN 22, 2024
Abpro Announces Filing of Registration Statement on Form S-4 in Connection with Business Combination Agreement with Atlantic Coastal Acquisition Corp. II
Read More →
SEP 21, 2023
Abpro to Become Publicly Traded via Merger with Atlantic Coastal Acquisition Corp. II
Read More →
SEP 21, 2022
Abpro Finalizes Strategic Partnership with Celltrion for Worldwide Development and Commercialization of a Cancer Treatment Bispecific Antibody
Read More →

News Prior to 2022

Publications

November 6, 2019
Abpro's TetraBi Platform for T-cell Engaging Antibodies targeting Claudin 18.2-expressing cancers Published for the 2019 SITC meeting
Read More →
MAY 16, 2019
Abpro's TetraBi Platform for T-cell Engaging Antibodies Published for the 2019 ASCO Meeting
Read More →
Back To Top